Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DGX Stock Forecast 2025-2026
$169.62
Current Price
$18.92B
Market Cap
Buy 9
Hold 10
Sell 0
Wall St Analyst Ratings
Distance to DGX Price Targets
+17.9%
To High Target of $200.00
+11.4%
To Median Target of $189.00
-6.4%
To Low Target of $158.69
DGX Price Momentum
-4.7%
1 Week Change
-2.3%
1 Month Change
+21.1%
1 Year Change
+12.4%
Year-to-Date Change
-5.8%
From 52W High of $179.99
+25.2%
From 52W Low of $135.47
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Quest Diagnostics (DGX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DGX and similar high-potential opportunities.
Latest DGX Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, DGX has a neutral consensus with a median price target of $189.00 (ranging from $158.69 to $200.00). The overall analyst rating is Buy (7.8/10). Currently trading at $169.62, the median forecast implies a 11.4% upside. This outlook is supported by 9 Buy, 10 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Westenberg at Piper Sandler, projecting a 17.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DGX Analyst Ratings
9
Buy
10
Hold
0
Sell
DGX Price Target Range
Low
$158.69
Average
$189.00
High
$200.00
Current: $169.62
Latest DGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2025 | JP Morgan | Lisa Gill | Neutral | Maintains | $190.00 |
| Apr 28, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $200.00 |
| Apr 23, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $194.00 |
| Apr 23, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $180.00 |
| Apr 23, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $185.00 |
| Apr 23, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $190.00 |
| Apr 9, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $189.00 |
| Apr 2, 2025 | Redburn Atlantic | Jamie Clark | Buy | Initiates | $195.00 |
| Mar 20, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $191.00 |
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $185.00 |
| Feb 4, 2025 | JP Morgan | Lisa Gill | Neutral | Maintains | $180.00 |
| Feb 3, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $178.00 |
| Feb 3, 2025 | Piper Sandler | David Westenberg | Neutral | Reiterates | $180.00 |
| Feb 3, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $170.00 |
| Jan 31, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $182.00 |
| Jan 31, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $175.00 |
| Jan 6, 2025 | Leerink Partners | Michael Cherny | Outperform | Upgrade | $174.00 |
| Dec 17, 2024 | Morgan Stanley | Erin Wright | Overweight | Upgrade | $172.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $182.00 |
| Dec 10, 2024 | Jefferies | Tycho Peterson | Buy | Assumes | $185.00 |
Quest Diagnostics Inc. (DGX) Competitors
The following stocks are similar to Quest Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DGX
Quest Diagnostics
mkt cap
19.69B
Quest Diagnostics Inc. (DGX) Financial Data
Quest Diagnostics Inc. has a market capitalization of $18.92B with a P/E ratio of 21.4x. The company generates $10.16B in trailing twelve-month revenue with a 8.8% profit margin.
Revenue growth is +12.1% quarter-over-quarter, while maintaining an operating margin of +13.9% and return on equity of +14.0%.
Valuation Metrics
Market Cap
$18.92B
Enterprise Value
$25.53B
P/E Ratio
21.4x
PEG Ratio
17.4x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
+12.1%
Gross Margin
+32.5%
Operating Margin
+13.9%
Net Margin
+8.8%
EPS Growth
+13.4%
Financial Health
Cash/Price Ratio
+1.0%
Current Ratio
1.4x
Debt/Equity
93.4x
ROE
+14.0%
ROA
+6.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Quest Diagnostics Inc. (DGX) Business Model
About Quest Diagnostics Inc.
What They Do
Provides diagnostic information services in healthcare.
Business Model
Quest Diagnostics generates revenue by offering a wide range of laboratory diagnostic services including routine blood tests and complex genetic testing to healthcare providers, hospitals, health plans, and government agencies. Its extensive network of laboratories and patient service centers ensures timely access to diagnostic information, which is essential for effective patient care.
Additional Information
The company emphasizes innovation and quality, positioning itself as a leader in the healthcare diagnostics sector. By leveraging advanced technology, Quest Diagnostics supports the growing demand for precision medicine, thus playing a vital role in early detection and personalized treatment strategies.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
55,000
CEO
Mr. James E. Davis
Country
United States
IPO Year
1996
Website
www.questdiagnostics.comQuest Diagnostics Inc. (DGX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
May 16, 2025
By Zacks Equity Research
Tale of the Tape
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
May 15, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Quest Diagnostics' "Know Your Health" survey shows one-third of Americans feel their doctors neglect preventive care discussions, with over half of younger generations facing access barriers to healthcare.
Why It Matters
The survey highlights gaps in preventive care and access to medical services, signaling potential demand for healthcare innovations and solutions, which could impact investments in health-focused companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
DGX has demonstrated strong performance over the past year, bolstered by solid core operations and successful acquisitions.
Why It Matters
DGX's strong performance and successful acquisitions indicate growth potential, which could lead to increased investor confidence and higher stock valuations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025, to shareholders on record as of July 7, 2025.
Why It Matters
Quest Diagnostics' dividend announcement indicates strong cash flow and profitability, signaling financial health and potentially attracting income-focused investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Quest Diagnostics (NYSE: DGX) CEO Jim Davis will present the company's strategy and market trends at the William Blair Growth Stock Conference on June 3, 2025, at 11:00 a.m.
Why It Matters
Jim Davis's presentation will provide insights into Quest Diagnostics' strategy and market trends, potentially impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores can help investors identify stocks with potential for superior performance, guiding strategic investment choices for better returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium research service offers Zacks Style Scores, aiding value, growth, and momentum investors in identifying strong stocks.
Why It Matters
The Zacks Style Scores can help identify strong stocks across investment styles, potentially enhancing portfolio performance and aiding in more informed investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About DGX Stock
What is Quest Diagnostics Inc.'s (DGX) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, Quest Diagnostics Inc. (DGX) has a median price target of $189.00. The highest price target is $200.00 and the lowest is $158.69.
Is DGX stock a good investment in 2025?
According to current analyst ratings, DGX has 9 Buy ratings, 10 Hold ratings, and 0 Sell ratings. The stock is currently trading at $169.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DGX stock?
Wall Street analysts predict DGX stock could reach $189.00 in the next 12 months. This represents a 11.4% increase from the current price of $169.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Quest Diagnostics Inc.'s business model?
Quest Diagnostics generates revenue by offering a wide range of laboratory diagnostic services including routine blood tests and complex genetic testing to healthcare providers, hospitals, health plans, and government agencies. Its extensive network of laboratories and patient service centers ensures timely access to diagnostic information, which is essential for effective patient care.
What is the highest forecasted price for DGX Quest Diagnostics Inc.?
The highest price target for DGX is $200.00 from David Westenberg at Piper Sandler, which represents a 17.9% increase from the current price of $169.62.
What is the lowest forecasted price for DGX Quest Diagnostics Inc.?
The lowest price target for DGX is $158.69 from at , which represents a -6.4% decrease from the current price of $169.62.
What is the overall DGX consensus from analysts for Quest Diagnostics Inc.?
The overall analyst consensus for DGX is neutral. Out of 31 Wall Street analysts, 9 rate it as Buy, 10 as Hold, and 0 as Sell, with a median price target of $189.00.
How accurate are DGX stock price projections?
Stock price projections, including those for Quest Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:46 AM UTC